Biotechnology News and Research

RSS

Mirna announces USPTO allows claims to therapeutic application of let-7 miRNA

Mirna Therapeutics, Inc. announced today that the USPTO has allowed claims related to the therapeutic application of let-7 in the regulation of oncogenes. The claims derive from a patent application that was submitted by Yale University and exclusively licensed to Mirna related to the pioneering work of Dr. Frank Slack, Professor of Molecular, Cellular & Developmental Biology at Yale University in New Haven, CT.

20 Oct 2010

MabCure announces agreement with Europe's medical centers to explore diagnostic test for ovarian cancer

Biotechnology company MabCure, Inc. today announced that it has signed a collaboration agreement with Catholic University, K.U. Leuven and University Hospital, UZ Leuven, Belgium, together comprising one of the largest and most reputable medical centers in Europe.

20 Oct 2010

NCI awards 20/20 GeneSystems $3 million to develop tests for targeted cancer therapies

20/20 GeneSystems, Inc. announced today at the AdvaMed MedTech Conference in Washington, D.C. that the company has been awarded nearly $3 million in grants from the National Cancer Institute's (NCI) Small Business Innovative Research (SBIR) Program to develop tests to help oncologists predict the effectiveness of targeted cancer therapies.

20 Oct 2010

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).

20 Oct 2010

Acorda announces data of GGF2 preclinical studies for focal ischemic stroke

Acorda Therapeutics, Inc, today announced that data from preclinical studies show that Glial Growth Factor 2 (GGF2) promoted functional recovery following a permanent focal ischemic stroke.

19 Oct 2010

d-Wise announces opening of office in the UK

d-Wise, provider of powerful business solutions for unique challenges of Life Sciences & Healthcare industries, announced the opening of its office in the UK. The company's UK efforts are spearheaded by James McDermott, a leader and key player in the pharmaceutical and biotechnology outsourcing arena.

19 Oct 2010

Adolor initiates ADL5945 Phase 2 proof-of-concept study for patients with OIC

Adolor Corporation today announced the initiation of a Phase 2 proof-of-concept (PoC) study of ADL5945 in patients suffering from opioid-induced constipation (OIC).

19 Oct 2010

Five Prime Therapeutics relocates into new drug discovery facility in South San Francisco

Five Prime Therapeutics, Inc., a leader in biologics, has relocated into its state-of-the-art drug discovery facility in South San Francisco. The new facility provides FivePrime with a two fold increase in square footage without significant incremental rental cost. The relocation includes an expanded laboratory facility for the Company to accelerate its innovative and proprietary protein therapeutic and antibody drug discovery platform.

19 Oct 2010

Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC

Amgen will review the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy) and will discuss how these results inform the appropriate use of erythropoiesis-stimulating agents (ESAs) for chronic renal failure (CRF) patients at today's meeting of the Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC).

19 Oct 2010

International investors take interest in Australia's biotechnology industry at ALSIS 2010

AusBiotech has kicked off its annual conference with a hugely successful Australasian Life Sciences Investment Summit 2010 in Melbourne today. The premier life science investment conference for Australia and the Asia-Pacific region attracted 150 investors from more than 100 organisations to hear 39 selected Australian biotechnology companies.

19 Oct 2010

ShangPharma prices initial public offering of American depositary shares

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its initial public offering of American depositary shares ("ADSs") was priced at $15 per ADS.

19 Oct 2010

JPO issues patent grant for Apricus's Femprox

Apricus Biosciences, Inc., backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Japanese Patent Office has issued a Decision to Grant a Patent for the Company's application on Femprox entitled, Compositions and Methods for Amelioration of Human Female Sexual Dysfunction.

19 Oct 2010

biOasis receives final report on Collaborative Research project from UBC

biOasis Technologies Inc. has received a final report detailing results achieved within the Collaborative Research project with The University of British Columbia (UBC) that was announced by the Company on June 2, 2009.

19 Oct 2010

Visiting biotech leader urges policymakers to support Australian innovation

The future of the Australian biotechnology industry relies on support from policymakers to ensure an economic environment and public policy regime that encourages innovation, says Jim Greenwood, president and CEO of Biotechnology Industry Organization (BIO). Speaking ahead of AusBiotech 2010, Mr Greenwood believes that strong government support is needed to ensure the continued success of Australian biotech.

18 Oct 2010

STB completes Fibrin Adhesive STat pre-IND submission to FDA

STB Lifesaving Technologies® today announced that is has completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA) for its lead product, the Fibrin Adhesive STat®, or (FAST®) dressing.

18 Oct 2010

Vertex commences VX-770 and VX-809 combination Phase 2a clinical trial for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.

18 Oct 2010

Goodwin enters new Biopharmaceutical Development and Manufacturing Agreement with multinational client

Goodwin Biotechnology, Inc., a full service contract biomanufacturing company, today announced that it has signed a new Biopharmaceutical Development and Manufacturing Agreement with a multinational biopharmaceutical client. According to the agreement, Goodwin will develop the process to manufacture a unique therapeutic monoclonal antibody conjugate for diagnostic imaging purposes.

18 Oct 2010

GeoVax Labs contributes article for HIV vaccine

Robert T. McNally, Ph.D., president and CEO of GeoVax Labs, Inc. a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has contributed an article on the search for an HIV vaccine to the October 15 issue of Genetic Engineering & Biotechnology News (GEN).

18 Oct 2010

Emollient creams on eczemous skin likely to make condition worse

New research at the University of Bath suggests that using emollient creams to relieve the symptoms of eczema could actually make the condition worse.

18 Oct 2010

Biocon, Pfizer enter global agreement to commercialize Insulin analog products

Biocon, Asia's premier biotechnology company, and Pfizer Inc. (NYSE: PFE), the world's leading biopharmaceutical company, today announced that they have entered into a strategic global agreement for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro.

18 Oct 2010

Biotechnology News and Research

Mirna announces USPTO allows claims to therapeutic application of let-7 miRNA

MabCure announces agreement with Europe's medical centers to explore diagnostic test for ovarian cancer

NCI awards 20/20 GeneSystems $3 million to develop tests for targeted cancer therapies

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Acorda announces data of GGF2 preclinical studies for focal ischemic stroke

d-Wise announces opening of office in the UK

Adolor initiates ADL5945 Phase 2 proof-of-concept study for patients with OIC

Five Prime Therapeutics relocates into new drug discovery facility in South San Francisco

Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC

International investors take interest in Australia's biotechnology industry at ALSIS 2010

ShangPharma prices initial public offering of American depositary shares

JPO issues patent grant for Apricus's Femprox

biOasis receives final report on Collaborative Research project from UBC

Visiting biotech leader urges policymakers to support Australian innovation

STB completes Fibrin Adhesive STat pre-IND submission to FDA

Vertex commences VX-770 and VX-809 combination Phase 2a clinical trial for cystic fibrosis

Goodwin enters new Biopharmaceutical Development and Manufacturing Agreement with multinational client

GeoVax Labs contributes article for HIV vaccine

Emollient creams on eczemous skin likely to make condition worse

Biocon, Pfizer enter global agreement to commercialize Insulin analog products

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News